

# New Ways to Tackle a Growing Health Care Dilemma - ESRD

J. Keith Melancon, M.D., F.A.C.S.

George Washington University

**Professor of Surgery** 

Chief, Transplant Surgery and Transplant Institute



# Thanks to our speaker!



#### Dr. Keith Melancon

- Director of the George Washington
   Transplant Institute
- Professor of surgery & the medical director of the Ron and Joy Paul Kidney Center
- Internationally renowned expert in paired kidney exchanges, ABO incompatible kidney transplantation, pancreas transplantation, and immunologic desensitization for organ transplants
- On four occasions set the world's record for largest paired kidney exchange



# Nietzsche – "The Birth of Tragedy"

Apollo



Dionysis



#### Why ESRD?

- Diabetes
- Hypertension
- Obesity
- Increased rates in minority population

# **Obesity**





# **Hypertension**






### **Diabetes**





#### Where is ESRD?






#### Who is ESRD?





# **Addressing Disparities**





# **Community Outreach**






### **Community Health Delivery Models**




# **CKD Increasing**






#### **Incidence ESRD**






### **Cost of ESRD**






# **Cost of ESRD vs Transplant**






# Outcomes for first-time wait-listed patients three years after listing in 2008, by age, race, & PRA Figure 7.5 (Volume 2)




Patients age 18 & older listed for a first-time, kidney-only transplant in 2008; transplanted patients may have subsequent outcomes in the three-year follow-up period.

#### Survival Difference: Transplant vs. Dialysis






# **Number of Kidney Transplants**






# Incidence of ESRD by Race






# **Graft Survival by Race**




#### Apol1 in Black Patients Nejm raj 2013






#### **African Ethnicities**



### Middle Passage



#### **Current Issues in Kidney Transplantation**

- Access
- Graft survival
- Sensitization
- Increasing organ numbers (DD and LD)

#### **Addressing Kidney Transplant Issues**

- Access outreach, education
- Sensitization- PKE (paired kidney exchange), desensitization
- Graft survival- novel immunosuppressive protocols, tolerance
- Donors sign up potential donors, educate potential living donors



→ Etc.

# Paired Kidney Exchange

#### **Chains Traditional Paired Exchange** Non Directed Two Pair Exchange Altruistic Donor Cluster #1 Three Pair Exchange #2 Cluster



#### **Desensitization**



#### Addressing Crisis – Increasing Organ Availability

- DCD/ECD organs
- Increasing living donation/ Altruistic donation
- ABO incompatible transplantation
- Desensitization protocols
- Paired kidney exchanges



#### **ABO** Incompatible Transplantation

- Must know and reduce ABO titer incompatibility (Antibody therapy, plasma exchange)
- Oftentimes better option than sensitized transplantation and timing better than PKE

#### **Desensitization Protocols**

- Must have luminex single bead technologies to isolate Antibody specificities and then tract titers during reduction therapy (Antibody therapy, plasma exchange, immunoglobulin therapy)
- Best fitted for living donor transplantation

# Paired Kidney Exchanges

- Utilize computerized matching algorithms to optimize organ utilization schemes in local, regional, and national organ exchanges
- Can be combined with ABO incompatible transplant and desensitization
- Domino exchanges can be fashioned to multiply successes



### **Disparities**

American Journal of Transplantation 2009; 9: 1–7 Wiley Periodicals Inc. © 2009 The Authors Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons

doi: 10.1111/j.1600-6143.2009.02845.x

# Impact of Medicare Coverage on Disparities in Access to Simultaneous Pancreas and Kidney Transplantation

J. K. Melancon<sup>a,\*</sup>, L. M. Kucirka<sup>b</sup>, L. E. Boulware<sup>c,d</sup>, N. R. Powe<sup>e</sup>, J. E. Locke<sup>b</sup>, R. A. Montgomery<sup>b</sup> and D. L. Segev<sup>b,d</sup>

<sup>a</sup>Department of Surgery, Georgetown University, Washington, DC

#### Introduction

The incidence of type 1 diabetes, a common cause of endstage renal disease (ESRD) (1), has been rising steadily in the United States (2). Studies have consistently shown that simultaneous pancreas and kidney transplantation (SPKT) is the best treatment for patients with both type 1 diabetes and ESRD, offering a significant survival advantage over kidney transplant (KT) alone (3–11). Significant improvements in diabetic neuropathy, gastropathy and vasculopathy have been demonstrated following SPKT (3–9), and it is the only method of reliably maintaining euglycemia (12). Long-term outcomes are excellent, with a 45% lower risk of death 10 years following SPKT compared to KT (13). Furthermore, the current allocation system favors combined

Department of Surgery, Department of Medicine, Johns Hopkins School of Medicine and Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore. MD

Department of Medicine, University of California, San Francisco, CA

<sup>\*</sup>Corresponding author: Joseph Keith Melancon, joseph.melancon@medstar.net



# Paired Kidney Exchanges

#### Paired Kidney Donor Exchanges and Antibody Reduction Therapy: Novel Methods to Ameliorate Disparate Access to Living Donor Kidney **Transplantation in Ethnic Minorities**

Joseph K Melancon, MD, FACS, Lee S Cummings, MD, Jay Graham, MD, Sandra Rosen-Bronson, PhD, Jimmy Light, MD, FACS, Chirag S Desai, MD, Raffaele Girlanda, MD, Seyed Ghasemian, MD, Joseph Africa, MD, Lynt B Johnson, MD, FACS

BACKGROUND: Currently ethnic minority patients comprise 60% of patients listed for kidney transplantation

in the US; however, they receive only 55% of deceased donor renal transplants and 25% of living donor renal transplants. Ethnic disparities in access to kidney transplantation result in increased morbidity and mortality for minority patients with end-stage renal disease. Because these patients remain dialysis dependent for longer durations, they are more prone to the development of HLA antibodies that further delay the possibility of receiving a successful

kidney transplant.

STUDY DESIGN: Two to 4 pretransplant and post-transplant plasma exchanges and IV immunoglobulin were

used to lower donor-specific antibody levels to less than 1:16 dilution; cell lytic therapy was used additionally in some cases. Match pairing by virtual cross-matching was performed to identify the maximal exchange benefit. Sixty candidates for renal transplantation were placed into 4

paired kidney exchanges and/or underwent antibody reduction therapy.

RESULTS: Sixty living donor renal transplants were performed by paired exchange pools and/or antibody

> reduction therapy in recipients whose original intended donors had ABO or HLA incompatibilities or both (24 desensitization and 36 paired kidney exchanges). Successful transplants were performed in 38 ethnic minorities, of which 33 were African American. Twenty-two recipients were white. Graft and patient survival was 100% at 6 months; graft function (mean serum creatinine 1.4 g/dL) and acute rejection rates (20%) have been comparable to traditional live donor kidney transplantation.

CONCLUSIONS: Paired kidney donor exchange pools with antibody reduction therapy can allow successful

transplant in difficult to match recipients. This approach can address kidney transplant disparities. (J Am Coll Surg 2011;212:740–747. © 2011 by the American College of Surgeons)

#### Results

Category  ABOi  Sensitized	Caucasian 7 5	3	Other 0	Mean Cr 1.38	Median Cr 1.3	Range of Cr	Pt/Graft Survival 100%/100%
			0	1.38	1.3	0.9 to 2.1	•
Sensitized	5						(12 months)
		4	1	1.34	1.3	0.9 to 2.3	100%/100% (9.9months)
ABOi	2	4	0	1.58	1.35	0.8 to 2.6	100%/100% (6.4months)
ABOc Non Sensitized	6	12	3	1.44	1.4	0.8 to 3.2	100%/100% (4.4 months)
ABOc Sensitized	2	10	1	1.38	1.3	0.9 to 1.9	100%/100% (7.4months)
Total	22	33	5	1.42	1.3	0.8 to 3.2	100%/100% (7.4months)
	ABOc on Sensitized ABOc Sensitized	ABOc 6 ABOc 2 Sensitized 2	ABOc 6 12 ABOc 2 10 Sensitized	ABOc 6 12 3  ABOc 2 10 1  Sensitized	ABOc on Sensitized 6 12 3 1.44  ABOc Sensitized 2 10 1 1.38	ABOc on Sensitized 6 12 3 1.44 1.4  ABOc Sensitized 2 10 1 1.38 1.3	ABOc on Sensitized 6 12 3 1.44 1.4 0.8 to 3.2  ABOc Sensitized 2 10 1 1.38 1.3 0.9 to 1.9

Table 1. Categories of patients with and follow up creatinine.

ABOi = ABO incompatible

ABOc = ABO compatible

#### Results

Categories	Local (PKDE)	US		
AA	55%	13.7%		
Whites	37%	66%		
Others	8%	20%		
Male	50%	61%		
Female	50%	39%		

Table 2. Demographics of local PKDE participants vs national living donor kidney recipients.




### PKE (Paired Kidney Exchange)

#### Multiple-Pair Matching 2-Pair Donation Pair 1 Pair 2 Donor 1 Donor 2 Recipient 2 Recipient 1 3-Pair Donation Pair 1 Pair 2 Pair 3 Donor 2 Donor 3 Donor 1 Recipient 3 Recipient 1 Recipient 2 Medscape




#### The Bonds that Tie





# **Paired Exchanges**





# World's Largest Kidney Exchange





# Questions?



#### Join us for next month's webinar!

Unique Strategies for Improving the Effectiveness of Exercise Training in Patients with Kidney Failure

#### Tuesday, January 17 1-2 p.m. (ET)

#### Dr. Ken Wilund

 Associate Professor in the Department of Kinesiology and Community Health and Division of Nutritional Sciences at the University of Illinois at Urbana-Champaign



#### Join us to learn about:

- Research regarding exercise in hemodialysis and transplant patients (What has worked, and what has not)
- Strategies for improving outcomes from exercise training interventions (How much and what type of exercise is recommended)
- Strategies for improving patient compliance with exercise and physical activity programs

Go to <u>www.KidneyFund.org/webinars</u> to learn more and register!